152 related articles for article (PubMed ID: 34002914)
1. Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
McDonald SA; Barclay ST; Innes HA; Fraser A; Hayes PC; Bathgate A; Dillon JF; Went A; Goldberg DJ; Hutchinson SJ
J Viral Hepat; 2021 Sep; 28(9):1246-1255. PubMed ID: 34002914
[TBL] [Abstract][Full Text] [Related]
2. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
3. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
Hutchinson SJ; Valerio H; McDonald SA; Yeung A; Pollock K; Smith S; Barclay S; Dillon JF; Fox R; Bramley P; Fraser A; Kennedy N; Gunson RN; Templeton K; Innes H; McLeod A; Weir A; Hayes PC; Goldberg D
Gut; 2020 Dec; 69(12):2223-2231. PubMed ID: 32217640
[TBL] [Abstract][Full Text] [Related]
4. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
[TBL] [Abstract][Full Text] [Related]
5. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study.
Kam LY; Yeo YH; Ji F; Henry L; Cheung R; Nguyen MH
Aliment Pharmacol Ther; 2024 Feb; 59(3):350-360. PubMed ID: 37937485
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
McDonald SA; Innes HA; Aspinall E; Hayes PC; Alavi M; Valerio H; Goldberg DJ; Hutchinson SJ
J Viral Hepat; 2017 Apr; 24(4):295-303. PubMed ID: 27885753
[TBL] [Abstract][Full Text] [Related]
7. Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C.
Jiang X; Song HJ; Chang CY; Wilson DL; Lo-Ciganic WH; Park H
Med Care; 2023 Aug; 61(8):505-513. PubMed ID: 37223993
[TBL] [Abstract][Full Text] [Related]
8. Improvements in liver transplant outcomes in patients with HCV/HIV coinfection after the introduction of direct-acting antiviral therapies.
Shimada S; Ivanics T; Kitajima T; Shamaa T; Rizzari M; Collins K; Yoshida A; Abouljoud M; Moonka D; Zhang J; Lu M; Nagai S
Transpl Infect Dis; 2022 Apr; 24(2):e13808. PubMed ID: 35157334
[TBL] [Abstract][Full Text] [Related]
9. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
11. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study.
Alavi M; Janjua NZ; Chong M; Grebely J; Aspinall EJ; Innes H; Valerio HM; Hajarizadeh B; Hayes PC; Krajden M; Amin J; Law MG; George J; Goldberg DJ; Hutchinson SJ; Dore GJ
J Hepatol; 2018 Mar; 68(3):393-401. PubMed ID: 29107152
[TBL] [Abstract][Full Text] [Related]
12. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
Flemming JA; Kim WR; Brosgart CL; Terrault NA
Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
14. In the Era of Direct-Acting Antivirals, Liver Transplant Delisting Due to Clinical Improvement for Hepatitis C Remains Infrequent.
Bittermann T; Reddy KR
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2389-2397.e2. PubMed ID: 32971230
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
[TBL] [Abstract][Full Text] [Related]
16. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
Petta S; Rini F; Calvaruso V; Cammà C; Ciminnisi S; Di Marco V; Giannini EG; Grimaudo S; Maria Pipitone R; Craxì A
Liver Int; 2020 Mar; 40(3):530-538. PubMed ID: 31507057
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
[TBL] [Abstract][Full Text] [Related]
19. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
[No Abstract] [Full Text] [Related]
20. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.
Tapper EB; Parikh ND; Green PK; Berry K; Waljee AK; Moon AM; Ioannou GN
Clin Gastroenterol Hepatol; 2020 May; 18(5):1197-1206.e7. PubMed ID: 31589975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]